Phase III trial of s 1 plus oxaliplatin (SOX) vs s 1 plus cisplatin (SP) combination chemotherapy for first line treatment of advanced gastric cancer (AGC) SOPP study.
4015Background: S 1 plus cisplatin (SP) is one of the standard first line chemotherapies for AGC in the East Asia. Oxaliplatin is generally less toxic and more convenient than cisplatin. This study.